JP5592360B2 - イミダゾピリミジノンおよびその使用 - Google Patents

イミダゾピリミジノンおよびその使用 Download PDF

Info

Publication number
JP5592360B2
JP5592360B2 JP2011515027A JP2011515027A JP5592360B2 JP 5592360 B2 JP5592360 B2 JP 5592360B2 JP 2011515027 A JP2011515027 A JP 2011515027A JP 2011515027 A JP2011515027 A JP 2011515027A JP 5592360 B2 JP5592360 B2 JP 5592360B2
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
group
product
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011515027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526247A (ja
JP2011526247A5 (OSRAM
Inventor
ジョン・ジョセフ・デッドマン
エリック・デイル・ジョーンズ
ジャン・ターン・レ
デイビッド・イアン・ローズ
ネーラナト・ティエントン
ニコラス・アンドリュー・バン・デ・グラフ
リサ・ジェーン・ウィンフィールド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tali Digital Ltd
Original Assignee
Avexa Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903406A external-priority patent/AU2008903406A0/en
Application filed by Avexa Ltd filed Critical Avexa Ltd
Publication of JP2011526247A publication Critical patent/JP2011526247A/ja
Publication of JP2011526247A5 publication Critical patent/JP2011526247A5/ja
Application granted granted Critical
Publication of JP5592360B2 publication Critical patent/JP5592360B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011515027A 2008-07-02 2009-07-02 イミダゾピリミジノンおよびその使用 Expired - Fee Related JP5592360B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2008903406 2008-07-02
AU2008903406A AU2008903406A0 (en) 2008-07-02 Imidazopyrimidinones and uses thereof
US16193109P 2009-03-20 2009-03-20
US61/161,931 2009-03-20
PCT/AU2009/000857 WO2010000031A1 (en) 2008-07-02 2009-07-02 Imidazopyrimidinones and uses thereof

Publications (3)

Publication Number Publication Date
JP2011526247A JP2011526247A (ja) 2011-10-06
JP2011526247A5 JP2011526247A5 (OSRAM) 2012-03-29
JP5592360B2 true JP5592360B2 (ja) 2014-09-17

Family

ID=41465416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011515027A Expired - Fee Related JP5592360B2 (ja) 2008-07-02 2009-07-02 イミダゾピリミジノンおよびその使用

Country Status (5)

Country Link
US (1) US8431581B2 (OSRAM)
EP (1) EP2291377B1 (OSRAM)
JP (1) JP5592360B2 (OSRAM)
CA (1) CA2729656A1 (OSRAM)
WO (1) WO2010000031A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5539978B2 (ja) * 2008-07-02 2014-07-02 アベキサ・リミテッド チアゾピリミジノンおよびその使用
EP2759544A1 (en) 2008-07-02 2014-07-30 Avexa Limited Compounds having antiviral properties
EP2540720B1 (en) 2010-02-26 2015-04-15 Japan Tobacco, Inc. 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
US11042897B2 (en) 2010-08-30 2021-06-22 Adap.Tv, Inc. System and method for determining effects of multi-channel media sources on multi-channel conversion events
WO2014133112A1 (ja) * 2013-03-01 2014-09-04 国立大学法人東京大学 オートタキシン阻害活性を有する8-置換イミダゾピリミジノン誘導体
HK1221420A1 (zh) 2013-05-10 2017-06-02 Gilead Apollo, Inc. Acc抑制剂和其用途
KR20160005364A (ko) 2013-05-10 2016-01-14 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
JP6434498B2 (ja) 2013-05-10 2018-12-05 ギリアド アポロ, エルエルシー Acc阻害剤及びその使用
MX2015015417A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
WO2015064714A1 (ja) * 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する1-置換イミダゾピリミジノン誘導体
BR112022010561A2 (pt) 2019-12-02 2022-11-16 Storm Therapeutics Ltd Compostos poli-heterocíclicos como inibidores de mettl3
CN116199605A (zh) * 2023-02-27 2023-06-02 上海睿腾医药科技有限公司 一种5-氯-2-羟基-二甲基苯磺酰胺的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101513402B (zh) 2001-08-10 2012-03-21 盐野义制药株式会社 抗病毒药
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
AU2006228278C1 (en) * 2005-03-31 2011-06-23 Msd Italia S.R.L. HIV integrase inhibitors
EP2269992A1 (en) * 2006-12-22 2011-01-05 Avexa Limited Bicyclic pyrimidinones for the treatment of viral infections

Also Published As

Publication number Publication date
EP2291377B1 (en) 2015-02-18
CA2729656A1 (en) 2010-01-07
US8431581B2 (en) 2013-04-30
US20110028487A1 (en) 2011-02-03
JP2011526247A (ja) 2011-10-06
WO2010000031A1 (en) 2010-01-07
EP2291377A1 (en) 2011-03-09
EP2291377A4 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
JP5592360B2 (ja) イミダゾピリミジノンおよびその使用
JP5535204B2 (ja) 抗ウイルス特性を有する化合物
EP2247601B1 (en) Thiazopyrimidinones and uses thereof
JP5208962B2 (ja) 二環式ピリミジノンおよびその使用
JP2022511819A (ja) ヘテロアリールジヒドロピリミジン誘導体及びb型肝炎感染症を治療する方法
JP2022513297A (ja) ヘテロアリールジヒドロピリミジン誘導体及びb型肝炎感染を治療する方法
TWI617553B (zh) 吖丁啶基氧苯基吡咯啶化合物
CN103080113A (zh) 7,9-氮基-4-氧代-4h-吡啶并[l,2-a]嘧啶-2-羧酸苄基酰胺抗病毒剂
ES2691548T3 (es) Sales de moduladores de PPAR y métodos para tratar desórdenes metabólicos
WO2022169882A1 (en) Methods and treatment of viral infection caused by sars-cov-2
HK1160645A (en) Compounds having antiviral properties
HK1131615B (en) Bicyclic pyrimidinones and uses thereof
JPWO1999043678A1 (ja) パーキンソン病の治療・予防剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140715

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140731

R150 Certificate of patent or registration of utility model

Ref document number: 5592360

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees